Bernstein maintains an outperform rating on Beam Therapeutics Inc. (BEAM)

Beam Therapeutics Inc. (NASDAQ:BEAM) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. On January 7, 2026, ...
Benzinga.com

Beam Therapeutics Stock Surges: What's Driving The Sudden Jump?

Beam has reported progress with the FDA on a potential accelerated approval path for BEAM‑302 and plans to file a Biologics License Application (BLA) for risto‑cel as early as the end of 2026. Beam ...
Benzinga.com

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial

On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...
AOL

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...